PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9334851-4	1997	Oral administration of nicotinamide with more than 62.5 mg/kg also significantly inhibited LPS-induced serum TNF-alpha production measured by ELISA and bioassay in Balb/c mice.	Niacinamide	23-35	tumor necrosis factor	Mus musculus	109-118	
12890690-5	2003	Through interaction with CD38 and inhibition of IL-1, IL-12, and TNF-alpha production, nicotinamide produces a mild TH2 bias.	Niacinamide	87-99	tumor necrosis factor	Mus musculus	65-74	
21926578-8	2012	MEASUREMENTS AND MAIN RESULTS: Nicotinamide effectively inhibited nuclear factor-kappaB translocation and binding activity as well as the production of tumor necrosis factor-alpha, nitrite/nitrate, and interleukin-6 in the lipopolysaccharide-stimulated RAW 264.7 and BV2 cells (p < .05, respectively) but exhibited weak antioxidant and radical-scavenging actions.	Niacinamide	31-43	tumor necrosis factor	Mus musculus	152-179	
8021488-1	1994	Nicotinamide and 3-aminobenzamide prevent TNF-alpha-mediated cytotoxicity, indicating that ADP-ribosylation plays a crucial role in this reaction.	Niacinamide	0-12	tumor necrosis factor	Mus musculus	42-51	
8890921-0	1996	Endogenous tumor necrosis factor-alpha production by a pancreatic beta-cell line: inhibitory effects of hydrocortisone and nicotinamide.	Niacinamide	123-135	tumor necrosis factor	Mus musculus	11-38	
8890921-5	1996	Nicotinamide of 5-10 mmol/l also reduced TNF-alpha mRNA and TNF-alpha protein levels in beta TC1 cells.	Niacinamide	0-12	tumor necrosis factor	Mus musculus	41-50	
8890921-5	1996	Nicotinamide of 5-10 mmol/l also reduced TNF-alpha mRNA and TNF-alpha protein levels in beta TC1 cells.	Niacinamide	0-12	tumor necrosis factor	Mus musculus	60-69	
2143488-4	1990	Niacinamide and 3-aminobenzamide, both inhibitors of ADP ribosylation and scavengers of free radicals, attenuated the class II expression induced by IFN-gamma and TNF.	Niacinamide	0-11	tumor necrosis factor	Mus musculus	163-166	
1280112-3	1992	Induction of NO synthase by TNF-alpha was prevented by inhibitors of poly(ADP-ribose) polymerase, namely nicotinamide, 3-methoxybenzamide and 3-aminobenzamide.	Niacinamide	105-117	tumor necrosis factor	Mus musculus	28-37	
1832087-9	1991	Tumor cell susceptibility to membrane-associated TNF activity, in contrast to recombinant (soluble) TNF, was greatly reduced in the presence of nicotinamide, an inhibitor of ADP-ribosyltransferase, suggesting that the mechanisms of lysis by these TNFs may be different.	Niacinamide	144-156	tumor necrosis factor	Mus musculus	49-52	
1832087-9	1991	Tumor cell susceptibility to membrane-associated TNF activity, in contrast to recombinant (soluble) TNF, was greatly reduced in the presence of nicotinamide, an inhibitor of ADP-ribosyltransferase, suggesting that the mechanisms of lysis by these TNFs may be different.	Niacinamide	144-156	tumor necrosis factor	Mus musculus	100-103	
1648452-1	1991	The two competitive inhibitors of ADP-ribosylation, nicotinamide and 3-aminobenzamide, have been reported to interfere with TNF-induced cell apoptosis, and there is evidence that they inhibit killer-induced target cell lysis as well.	Niacinamide	52-64	tumor necrosis factor	Mus musculus	124-127	
2967329-5	1988	Two inhibitors of ADP-ribosylation, namely 3-aminobenzamide and nicotinamide, prevented TNF-mediated cytotoxicity.	Niacinamide	64-76	tumor necrosis factor	Mus musculus	88-91	
2151129-0	1990	Protective effect of nicotinamide and 3-aminobenzamide on islet cell damage induced by gamma-interferon and tumor necrosis factor.	Niacinamide	21-33	tumor necrosis factor	Mus musculus	108-129	
2151129-5	1990	In a medium containing 20 mM of nicotinamide, together with IFN-gamma and TNF, specific 51Cr release was significantly reduced (12 +/- 3%, p less than 0.01).	Niacinamide	32-44	tumor necrosis factor	Mus musculus	74-77	
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Niacinamide	77-80	tumor necrosis factor	Mus musculus	335-343	
2967329-7	1988	In the absence of actinomycin D, treatment of L929 cells with TNF also increased ADP-ribosylation, and the cytotoxic action of TNF was inhibited by nicotinamide.	Niacinamide	148-160	tumor necrosis factor	Mus musculus	62-65	
2967329-7	1988	In the absence of actinomycin D, treatment of L929 cells with TNF also increased ADP-ribosylation, and the cytotoxic action of TNF was inhibited by nicotinamide.	Niacinamide	148-160	tumor necrosis factor	Mus musculus	127-130